• Something wrong with this record ?

Preclinical safety and electrical performance of novel atrial leadless pacemaker with dual-helix fixation

M. Rashtian, RS. Banker, P. Neuzil, K. Breeman, P. Nee, N. Badie, K. Victorine, D. Ligon, MK. Rippy, Z. Eldadah, R. Doshi, DJ. Cantillon, RE. Knops

. 2022 ; 19 (5) : 776-781. [pub] 20220120

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018568

BACKGROUND: Complications associated with transvenous pacemakers, specifically those involving the lead or subcutaneous pocket, may be avoided with leadless pacemakers (LPs). The safety and efficacy of single-chamber right ventricular LPs have been demonstrated, but their right atrium (RA) use poses new design constraints. OBJECTIVES: The purpose of this study was to evaluate the implant success, electrical performance, and safety of a novel RA LP design in benchtop and preclinical studies. METHODS: A new LP was designed with a dual-helix fixation mechanism specific to the RA anatomy. A 12-week preclinical ovine study was conducted to evaluate implant success, electrical performance, mechanical stability, and safety in vivo, with supporting benchtop measurements to quantify the mechanical forces needed for device retrieval and dislodgment. RESULTS: LPs were successfully implanted in all 10 ovine subjects with no complications. The pacing capture threshold improved significantly over time from implant to week 12 (1.1 ± 0.7 V vs 0.4 ± 0.2 V, P = .008). Sensing amplitudes and pacing impedances were stable from implant to week 12 (4.8 ± 1.8 mV vs 6.0 ± 1.9 mV, P = .160; and 393 ± 77 Ω vs 398 ± 65 Ω, P = .922, respectively). Gross pathology and microscopic histology revealed no adverse interactions and no evidence of device dislodgment or clinically significant myocardial perforation. Benchtop ex vivo porcine atrial tissue measurements revealed greater pull forces required to dislodge the LP vs transvenous active fixation lead (0.42 ± 0.18 lbf vs 0.29 ± 0.08 lbf, P = .020), and greater rotational forces required for deliberate extraction (0.28 ± 0.04 lbf vs 0.14 ± 0.07 lbf, P <.001). CONCLUSION: The novel atrial LP demonstrated successful implantation, with acceptable electrical performance, mechanical stability, and safety in a 12-week preclinical study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018568
003      
CZ-PrNML
005      
20220804134852.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hrthm.2022.01.021 $2 doi
035    __
$a (PubMed)35066177
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rashtian, Mayer $u Huntington Hospital, Pasadena, California. Electronic address: mrashtianmd@gmail.com
245    10
$a Preclinical safety and electrical performance of novel atrial leadless pacemaker with dual-helix fixation / $c M. Rashtian, RS. Banker, P. Neuzil, K. Breeman, P. Nee, N. Badie, K. Victorine, D. Ligon, MK. Rippy, Z. Eldadah, R. Doshi, DJ. Cantillon, RE. Knops
520    9_
$a BACKGROUND: Complications associated with transvenous pacemakers, specifically those involving the lead or subcutaneous pocket, may be avoided with leadless pacemakers (LPs). The safety and efficacy of single-chamber right ventricular LPs have been demonstrated, but their right atrium (RA) use poses new design constraints. OBJECTIVES: The purpose of this study was to evaluate the implant success, electrical performance, and safety of a novel RA LP design in benchtop and preclinical studies. METHODS: A new LP was designed with a dual-helix fixation mechanism specific to the RA anatomy. A 12-week preclinical ovine study was conducted to evaluate implant success, electrical performance, mechanical stability, and safety in vivo, with supporting benchtop measurements to quantify the mechanical forces needed for device retrieval and dislodgment. RESULTS: LPs were successfully implanted in all 10 ovine subjects with no complications. The pacing capture threshold improved significantly over time from implant to week 12 (1.1 ± 0.7 V vs 0.4 ± 0.2 V, P = .008). Sensing amplitudes and pacing impedances were stable from implant to week 12 (4.8 ± 1.8 mV vs 6.0 ± 1.9 mV, P = .160; and 393 ± 77 Ω vs 398 ± 65 Ω, P = .922, respectively). Gross pathology and microscopic histology revealed no adverse interactions and no evidence of device dislodgment or clinically significant myocardial perforation. Benchtop ex vivo porcine atrial tissue measurements revealed greater pull forces required to dislodge the LP vs transvenous active fixation lead (0.42 ± 0.18 lbf vs 0.29 ± 0.08 lbf, P = .020), and greater rotational forces required for deliberate extraction (0.28 ± 0.04 lbf vs 0.14 ± 0.07 lbf, P <.001). CONCLUSION: The novel atrial LP demonstrated successful implantation, with acceptable electrical performance, mechanical stability, and safety in a 12-week preclinical study.
650    _2
$a zvířata $7 D000818
650    _2
$a kardiostimulace umělá $7 D002304
650    _2
$a design vybavení $7 D004867
650    _2
$a srdeční síně $7 D006325
650    _2
$a lidé $7 D006801
650    12
$a lipopolysacharidy $7 D008070
650    12
$a kardiostimulátor $7 D010138
650    _2
$a protézy a implantáty $7 D019736
650    _2
$a ovce $7 D012756
650    _2
$a prasata $7 D013552
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Banker, Rajesh S $u Hoag Hospital, Newport Beach, California
700    1_
$a Neuzil, Petr $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Breeman, Karel $u Academic Medical Center, Amsterdam, The Netherlands
700    1_
$a Nee, Peter $u Abbott, Sunnyvale, California
700    1_
$a Badie, Nima $u Abbott, Sunnyvale, California
700    1_
$a Victorine, Keith $u Abbott, Sunnyvale, California
700    1_
$a Ligon, David $u Abbott, Sunnyvale, California
700    1_
$a Rippy, Marian K $u Rippy Pathology Solutions, Inc., Woodbury, Minnesota
700    1_
$a Eldadah, Zayd $u MedStar Health, Washington, DC
700    1_
$a Doshi, Rahul $u HonorHealth Research Institute, Scottsdale, Arizona
700    1_
$a Cantillon, Daniel J $u Cleveland Clinic Foundation, Cleveland, Ohio
700    1_
$a Knops, Reinoud E $u Academic Medical Center, Amsterdam, The Netherlands
773    0_
$w MED00156180 $t Heart rhythm $x 1556-3871 $g Roč. 19, č. 5 (2022), s. 776-781
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35066177 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134846 $b ABA008
999    __
$a ok $b bmc $g 1822257 $s 1169811
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 19 $c 5 $d 776-781 $e 20220120 $i 1556-3871 $m Heart rhythm $n Heart Rhythm $x MED00156180
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options